Source: Mediterranee Infection

COVID-IHU #15

Version 1 du 27 Mai 2020
Early diagnosis and management of COVID-19 patients: a real-life cohort study of 3,737 patients, Marseille, France

Abstract

Background:
In our institute in Marseille, France, we proposed early and massive screening for coronavirus disease 2019 (COVID-19). Hospitalization and early treatment with hydroxychloroquine and azithromycin (HCQ-AZ) was proposed for the positive cases.

Methods:
We retrospectively report the clinical management of 3,737 patients, including 3,054 (81.7%) treated with HCQ-AZ for at least three days and 683 (18.3%) patients treated with other methods (“others”). Outcomes were death, transfer to the intensive care unit (ICU), ≥ 10 days of hospitalization and viral shedding.

Results:
By testing 101,522 samples by polymerase chain reaction (PCR) from 65,993 individuals, we diagnosed 6,836 patients (10.4%), including 3,737 included in our cohort. The mean age was 45 (sd 17) years, 45% were male, and the fatality rate was 0.9%.

We performed 2,065 low-dose computed tomography (CT) scans highlighting lung lesions in 581 of the 933 (62%) patients with minimal clinical symptoms (NEWS score = 0).

A discrepancy between spontaneous dyspnoea, hypoxemia and lung lesions was observed. Clinical factors (age, comorbidities, NEWS-2 score), biological factors (lymphopenia; eosinopenia; decrease in blood zinc; and increase in D-dimers, lactate dehydrogenase (LDH), creatinine phosphokinase (CPK), and c-reactive protein (CRP)) and moderate and severe lesions detected in low-dose CT scans were associated with poor clinical outcome.

Treatment with HCQ-AZ was associated with a decreased risk of transfer to the ICU or death (HR 0.19 0.12-0.29), decreased risk of hospitalization ≥10 days (odds ratios 95% CI 0.37 0.26-0.51) and shorter duration of viral shedding (time to negative PCR: HR 1.27 1.16-1.39).

QTc prolongation (>60 ms) was observed in 25 patients (0.67%) leading to the cessation of treatment in 3 cases. No cases of torsade de pointe or sudden death were observed.

Conclusion
Early diagnosis, early isolation and early treatment with at least 3 days of HCQ-AZ result in a significantly better clinical outcome and contagiosity in patients with COVID-19 than other treatments.

Long-term follow-up to screen for fibrosis will be the next challenge in the management of COVID-19.


Related:
YALE: Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis (HCQ – AZ)


Hydroxychloroquine: Turkey continues using drug despite WHO pause


Despite WHO’s Warning, India Continues Use of Hydroxychloroquine as Prevention Measure


TANG ET AL, BMJ: Favourable data for hydroxychloroquine removed between study’s draft and final print


Hydroxychloroquine is currently being used with great success – Qatar has a case fatality rate of only 0.04% with 21 deaths out of 43,714 cases.


Hospital in Piauí heals people from covid-19 and empties ICUs with hydroxychloroquine

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Professor Borody Talks about Early Treatment of COVID-19 – Part 1 – September 2020

We treat them for 10 days using an appropriate dose of ivermectin, doxycycline daily and zinc daily.

They all actually have activity against the intracellular multiplication of the virus and from published data you can read that most of the results have been close to 100 percent cure there was one that used the lower level and got 92 percent cure but it’s just hard to believe how simple it is to cure coronavirus.

Read More »